Domp’s Program in NAION Selected for Landmark FDA Commissioners National Priority Voucher Program
One of just nine voucher recipients chosen and the only one in…
Milliken & Company Launches Millad ClearX 9000: The Clear Choice for Polypropylene
Delivers exceptional clarity with lower additive levels, streamlining production and expanding formulation…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
PPG launches PPG HI-GARD Non-Methanol hard coating for ophthalmic lenses
Works with existing systems, helps lens makers stay ahead of global regulationsPITTSBURGH--(BUSINESS…
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence…